News

European Pharmaceutical manufacturer || Paradigm4 and Alnylam partnership to accelerate RNAi- based drug discovery

Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the pace and productivity of Alnylam’s RNAi therapeutics pipeline.

whitepages icon x

GenomeWeb: Paradigm4 Moves Into Single-Cell Data, Helps Pharma Address COVID-19

Neil Versel

whitepages icon x

54gene Enlists Paradigm4’s Science-Ready Data Solution for its African Health Information Ecosystem

12 JANUARY 2021: Paradigm4, specialist in scientific data management and scalable computation, has signed an agreement with 54gene, a health technology company deriving insights from the world’s most diverse populations to solve some of healthcare’s biggest challenges. The agreement will allow 54gene to use Paradigm4’s REVEALTM Biobank app to explore,

whitepages icon x

International Pharmaceutical Technology | 1 Trillion Cells, 50 Million Individuals

Calculating the true value of scientific data storage platforms is the goal of every developer. With millions of cells to analyze, digital solutions are the key